MedTrace Logo

Evaluation of MG53 (TRIM72) Levels in Women With Polycystic Ovary Syndrome: An Observational Study

NCT07094776 · Status: ENROLLING_BY_INVITATION · Type: OBSERVATIONAL · Enrollment: 128

Last updated 2025-08-06

No results posted yet for this study

Summary

Purpose of the Study:

This study is being conducted to examine a protein called MG53 (also known as TRIM72) in women with polycystic ovary syndrome (PCOS). MG53 is involved in cell membrane repair and may play a role in insulin resistance, which is common in PCOS.

Study Procedures:

Women between 18 and 45 years of age will be invited to participate. The study population will include both women diagnosed with PCOS and healthy controls. A single blood sample (approximately 5 mL) will be collected from each participant. MG53 levels will be measured using an ELISA laboratory assay.

Significance of the Study:

Analysis of MG53 levels in relation to hormonal and metabolic markers may help determine whether MG53 is associated with insulin resistance and other characteristics of PCOS.

Conditions

  • Polycystic Ovary Syndrome (PCOS)
  • Insulin Resistance Syndrome

Interventions

OTHER

No intervention (observational study)

This is an observational study. No drugs, devices, or treatments are administered. Participants only provide a single blood sample for MG53 and routine metabolic measurements.

Sponsors & Collaborators

  • Havva Betül Bacak

    lead OTHER_GOV

Principal Investigators

  • Enes S Coşkun, M.D. · University of Health Sciences, Gaziosmanpaşa Training and Research Hospital

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-06-18
Primary Completion
2025-08-20
Completion
2025-08-20

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07094776 on ClinicalTrials.gov